A former Sun Pharmaceutical sales employee has a filed a lawsuit claiming retaliation for objecting to alleged off-label marketing practices, the second time in four months that one of the world’s largest generic drug makers has been accused of such a move amid rising scrutiny of its business practices.

In her lawsuit, Sandra Hagenbrock, a former national account director, claimed that company managers flouted internal policies prohibiting off-label marketing. Instead, the drug maker tried to “aggressively solicit opportunities to present off-label information to decision-makers (notably, physicians and health plans) about its drugs.” Among them was the Yonsa treatment for prostate cancer.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy